GeneDx Holdings Corp. 8-K

What Happened
GeneDx Holdings Corp. (WGS) filed an 8-K reporting the results of its Annual Meeting of Stockholders held June 18, 2026. There were 29,675,547 shares of Class A common stock outstanding as of the April 20, 2026 record date. Stockholders approved all proposals: the election of one Class II director (Katherine Stueland) for a three‑year term, ratification of Ernst & Young LLP as the independent auditor for fiscal 2026, an advisory “say-on-pay” approval for executive compensation, and a non‑binding advisory vote favoring annual (one‑year) frequency for future executive compensation votes.

Key Details

• Class II Director election (one seat): Katherine Stueland — Votes For: 18,325,894; Votes Withheld: 5,893,466; Broker Non‑Votes: 3,409,327.
• Auditor ratification: Ernst & Young LLP — For: 27,466,639; Against: 158,884; Abstentions: 3,164.
• Advisory vote on executive compensation (say‑on‑pay): For: 22,705,946; Against: 1,471,593; Abstentions: 41,821.
• Advisory vote on frequency of future say‑on‑pay votes (non‑binding): 1 year: 23,816,121; 2 years: 24,246; 3 years: 358,017; Abstentions: 20,976.

Why It Matters
These results confirm corporate governance continuity: the incumbent CEO Katherine Stueland was elected to the Class II board seat and Ernst & Young will remain the company’s auditor for 2026, which affects oversight and financial reporting continuity. The advisory approval of executive compensation and the preference for annual advisory votes reflect shareholder sentiment on pay disclosure and governance practices; the frequency vote is non‑binding but signals investor expectations for regular compensation review.